Investor Presentaiton

The opportunities - USA Upcoming LOE opportunities will be dominated by differentiated generics products Estimated worldwide sales of all products losing US patent protection in the year before patent expiry USD billions 59 59 41 37 37 36 36 33 29 6 55 20 22 15 20 26 Differentiated generics ■ Biologics ■ 22 Inhalers, intranasals Injectables ■ Transdermals ■ Others 27 22 19 - Orals 16 14 15 11 10 2011 12 13 14 15 16 17 18 2019 46 68 47 60 57 36 44 43 51 Number of products Pipeline being augmented with - Intranasal, Derma ointments/creams, Injectables & Specialty Oral Solids (Oncology) Mckinsey LOE - Loss of Exclusivity

View entire presentation